Floatz logo

Cediranib

Adenocarcinoma of the Pancreas

University Health Network, TorontoSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
(+)-VINCRISTINE
Georgetown University
Phase 3BBB
azd6244
AstraZeneca
Phase 2BB
Veliparib
National Cancer Institute (NCI)
Phase 2BB
Temsirolimus
Massachusetts General Hospital
Phase 2B

View all 47 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →